FP
ACOR

Foundry Partners’s Acorda Therapeutics ACOR Stock Holding History

Foundry Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-388
Closed -$977K – 451
2017
Q1 		$977K Sell
388
-1
-0.3% -$2.88K 0.04% 348
2016
Q4 		$877K Buy
+389
New +$925K 0.04% 354

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Foundry Partners's ACOR Position: Q2 2017 in Review

Foundry Partners sold out of Acorda Therapeutics (ACOR) in Q2 2017, closing a stake of 388 shares — an estimated $977K sold.

Foundry Partners first reported a position in ACOR in Q4 2016 and held it in 2 quarters. The position peaked at $977K in Q1 2017. 151 funds tracked by Wall St. Rank hold ACOR as of Q2 2017.

  • Foundry Partners reported no remaining Acorda Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Foundry Partners sold 388 Acorda Therapeutics shares in Q2 2017, an estimated $977K.
  • Foundry Partners first reported a position in Acorda Therapeutics in Q4 2016 and held it in 2 quarters.
  • Foundry Partners's Acorda Therapeutics position peaked at $977K in Q1 2017.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2017.

Based on Foundry Partners's 13F filing for Q2 2017, filed 2 Aug 2017.